Sight Sciences Inc SGHT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SGHT is a good fit for your portfolio.
News
-
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
-
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
-
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
-
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
-
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
-
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
-
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
-
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
Trading Information
- Previous Close Price
- $5.38
- Day Range
- $5.19–5.40
- 52-Week Range
- $1.04–11.20
- Bid/Ask
- $5.00 / $5.27
- Market Cap
- $259.66 Mil
- Volume/Avg
- 160,997 / 178,734
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.23
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 214
- Website
- https://www.sightsciences.com
Comparables
Valuation
|
Metric
|
SGHT
|
STAA
|
RXST
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 44.56 | — |
Price/Book Value | 2.20 | 5.86 | 12.24 |
Price/Sales | 3.23 | 7.10 | 21.01 |
Price/Cash Flow | — | 41.32 | — |
Price/Earnings
SGHT
STAA
RXST
Financial Strength
|
Metric
|
SGHT
|
STAA
|
RXST
|
|---|---|---|---|
Quick Ratio | 12.44 | 4.90 | 7.05 |
Current Ratio | 13.29 | 5.62 | 8.06 |
Interest Coverage | −9.25 | — | −15.68 |
Quick Ratio
SGHT
STAA
RXST
Profitability
|
Metric
|
SGHT
|
STAA
|
RXST
|
|---|---|---|---|
Return on Assets (Normalized) | −23.43% | 8.13% | −17.04% |
Return on Equity (Normalized) | −31.87% | 10.15% | −21.78% |
Return on Invested Capital (Normalized) | −22.96% | 8.15% | −20.20% |
Return on Assets
SGHT
STAA
RXST
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Shfjzcwgq | Wvfjwft | $182.7 Bil | |
SYK
| Stryker Corp | Xkvjwwjdh | Yyw | $124.6 Bil | |
MDT
| Medtronic PLC | Hyhryjpwf | Qfrwrf | $105.0 Bil | |
BSX
| Boston Scientific Corp | Zhqmdjgb | Gbzsnt | $99.9 Bil | |
EW
| Edwards Lifesciences Corp | Qplgmngl | Lkzxhf | $52.0 Bil | |
DXCM
| DexCom Inc | Brhcyyhcr | Rrtwc | $51.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Mxckdxpc | Xzfy | $24.9 Bil | |
ALGN
| Align Technology Inc | Kdkvjvcsv | Jlrsfg | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Wdsprny | Byzvq | $18.2 Bil | |
PODD
| Insulet Corp | Rlwzlzng | Njgpkq | $11.6 Bil |